Research linking obesity and asthma suggests that weight loss can reduce eotaxin levels, a key inflammatory mediator. The study found that obese patients experienced significant reductions in eotaxin levels after losing weight, offering new hope for treating debilitating asthma symptoms.
The studies demonstrated that rhIGF-1 administration causes a prompt increase in blood IGFBP-3 levels in patients with IGF-1 deficiency. The findings suggest that IGFBP-3 is recruited into the bloodstream or IGF-1 is stabilized by binding to IGFBP-3, which may help guide optimal dosing of rhIGF-1.
Tercica has presented human and animal safety data showing no immunotoxic effects with long-term rhIGF-1 treatment. The data also demonstrate a reduction in the incidence of some endocrine cancers in animals, providing further evidence supporting the long-term safety of rhIGF-1 therapy.
A study examining Seroquel treatment for bipolar depression found significant improvements in quality of life measures, with the most common adverse events including dry mouth and sedation. The results are promising for managing depressive symptoms associated with bipolar disorder.
A study examined the effect of SEROQUEL on cognitive function in patients with schizophrenia, showing improved overall cognition. Another analysis found that patients taking atypical antipsychotics had better treatment compliance compared to those taking conventional antipsychotics.
A study found that approximately 30,000 US children have short stature due to non-growth hormone deficiency Primary IGF-1 deficiency. This suggests one-third to half of idiopathic short stature cases can be re-classified as Primary IGFD.
The study demonstrates a statistically significant and clinically meaningful benefit of pegaptanib in treating wet AMD. Treatment with pegaptanib reduces the risk of visual-acuity loss, promotes stability of vision, and may lead to more visual improvement in some patients.
A large phase III trial showed that sequential treatment with ELLENCE delivered superior disease-free and overall survival compared to FEC 100 alone. The sequential regimen resulted in a 17% reduction in relapse risk and a 23% reduction in mortality risk.
A study presented at the SABCS showed a 30 percent reduction in breast cancer recurrence when postmenopausal women with hormone-receptor-positive breast cancer were switched from tamoxifen to AROMASIN after 2-3 years. This finding supports ASCO recommendations for adjuvant therapy with aromatase inhibitors.
The ARIES trial shows CRESTOR 10mg reduced LDL-C by 37%, compared to 32% for atorvastatin, with higher response rates among African-American patients. CRESTOR also improved HDL-C levels and reduced non-HDL-C and total cholesterol.
The study confirms that patients benefit from two years of treatment with Macugen for wet AMD, demonstrating a statistically significant 45% treatment benefit. Longer-term use may be beneficial for patients suffering from this chronic disease.
A study published in Nature Medicine reveals that heparin works by blocking the activation of the complement pathway, a series of inflammatory proteins involved in pregnancy loss and placental injury. This new mechanism suggests potential targeted therapy for patients with antiphospholipid syndrome.
A study of US patients treated with ZYVOX for complicated skin infections caused by MRSA found significantly better clinical cure rates (92% vs. 86%) and reduced healthcare costs ($652 per patient). The treatment's oral option also facilitated earlier discharge, contributing to cost savings.
The CYPHER Stent significantly reduces major adverse cardiac events in women, including diabetics and smokers, by up to 90% over conventional bare metal stents. The analysis of 345 female patients showed a low target lesion revascularization rate, indicating fewer procedures and better outcomes for women with heart disease.
A sub-study of the FASG-05 trial found that a higher dose of ELLENCE improved disease-free and overall survival in patients with node-positive breast cancer. The study also showed a low risk of adverse cardiac events, despite concerns about cardiotoxicity.
The CAMPTOSAR plus cisplatin regimen demonstrated improved one-year survival rates (59.2%) and response rates (31%) compared to current standard treatments. Patient toxicities were also significantly reduced, with fewer grade 3-4 neutropenia and thrombocytopenia cases.
A Phase III trial found that CAMPTOSAR combinations with select targeted agents improve survival for MCRC patients. The combination of Avastin and IFL yields an average survival of 25.1 months compared to 15.8 months with IFL alone. A Phase II trial also shows the efficacy of Erbitux plus CAMPTOSAR and infusional FOLFIRI in EGFR-expres...
A new sequential dose-dense chemotherapy regimen including ELLENCE significantly improves survival in high-risk breast cancer patients, with estimated 3-year relapse-free and overall survival rates of 80% and 90%, respectively. The study confirms the benefits of this optimal dose dense therapy for women at highest risk of recurrence.
A clinical trial of 370 patients found that Pfizer's VFEND was as effective as the two-drug standard of amphotericin B and fluconazole in treating Candidemia. The treatment successfully cleared Candida from the blood, with a response rate of 41% at 12 weeks.
A $3.6M study aims to demonstrate the effectiveness of linking CT lung cancer screening to smoking-cessation programs. Dr. Claudia Henschke's research will use advanced image analysis software to investigate this connection.
A new study published in Urology found that men taking AVODART for four years experienced a significant reduction in urinary symptoms and prostate volume, with an average symptom improvement of 6.1 points on the AUA-SI. Long-term treatment also resulted in low incidence of drug-related side effects.
A large international study found that patients switched from tamoxifen to AROMASIN after 2-3 years experienced a significant reduction in breast cancer recurrence and longer disease-free survival. The study suggests a potential new treatment option for post-menopausal women with estrogen-receptor positive breast cancer.
The PAVE study found that biventricular pacing improved cardiac function and functional capacity in patients with chronic atrial fibrillation undergoing ablate and pace therapy. In contrast, the DINAMIT study showed no overall mortality benefit of implantable cardioverter defibrillator (ICD) therapy in patients following a recent acute...
A new study found that the birth control patch had a higher percentage of perfect dosing cycles (88.7%) compared to oral contraceptives (79.2%). This led to better contraceptive efficacy and reduced risk of unplanned pregnancy. The results suggest that the patch may be a more convenient and simple option for women using birth control.
A new study shows that inhaled nitric oxide is an effective treatment for hypoxic respiratory failure (HRF) in newborns, saving over $440,000 per 100 cases compared to the invasive ECMO procedure. This breakthrough therapy benefits patients and reduces costs without compromising treatment outcomes.
Researchers found BMAA in increasingly higher concentrations in the food chain of Chamorro people on Guam, potentially linking their diet to neurodegenerative diseases like ALS-PDC. Biomagnification of BMAA was also detected in Canadian patients with similar conditions.
In a phase II clinical study, exemestane demonstrated a higher tumor response rate (41%) compared to tamoxifen (17%) in shrinking tumors. Exemestane was also well-tolerated with fewer side effects than tamoxifen.
A study found that patients initially treated with voriconazole had better outcomes and incurred fewer antifungal drug costs than those treated initially with amphotericin B. The results showed a 53% success rate for voriconazole-treated patients compared to 32% for amphotericin B.
The ADOPT-A trial demonstrates the effectiveness of the AF Suppression algorithm in reducing symptomatic atrial fibrillation (AF) burden. The study found a significant 25% reduction in symptomatic AF episodes in patients using the algorithm compared to those with standard pacemaker indications.
The study presents data on quetiapine fumarate's efficacy in managing symptoms of acute mania in patients with bipolar disorder. The medication achieved significant responses in 48.1% of patients, with a high completion rate compared to the placebo group.
A new clinical trial confirms zaleplon's safety and tolerability for the long-term treatment of insomnia, lasting up to 12 months. The medication showed no withdrawal symptoms upon discontinuation, making it a good option for chronic insomnia sufferers.
Researchers have discovered a new drug, pifithrin-alpha, that can protect healthy tissues from radiation damage and reduce side effects. The treatment strategy may allow for higher doses of therapy to be administered, improving cure rates.